Prognosis and Therapies in Non-Clear Cell Renal Cell Carcinomas
Open Access
Abstract
Background/Objectives: Non-clear cell renal cell carcinoma (nccRCC) comprises biologically heterogeneous renal malignancies with distinct molecular drivers, clinical behavior, and therapeutic responses. This review summarizes prognosis and systemic therapy and evaluates emerging histology-specific and biomarker-directed approaches. Methods: We analyzed overall survival by histology in the SEER 17 Registries database (2000–2022) and conducted a narrative review of trials, guidelines, and translational studies. The ICD-O-3-defined population included 43,966 adults; 43,789 with known survival time were included in survival analyses. Results: Median follow-up was 96 months. Compared with papillary RCC, adjusted HRs were 0.67 (95% CI 0.64–0.70) for chromophobe RCC, 3.73 (3.37–4.11) for collecting duct carcinoma, 0.97 (0.80–1.17) for oncocytic tumors, and 33.23 (27.47–40.20) for medullary carcinoma. VEGFR- and MET-directed therapies and immune checkpoint inhibitor combinations show activity that varies by histology. Conclusions: nccRCC should be studied and managed as a collection of distinct entities. Registry associations require cautious interpretation because of residual confounding, evolving classification, and non-proportional hazards; subtype-specific trials and molecular stratification remain priorities.Keywords
All Related Versions
This publication has 52 references indexed in Scilit:
- Tumor-informed ctDNA surveillance after radical nephrectomy and level IV IVC thrombectomy for clear cell renal cell carcinoma: Early detection of molecular residual diseaseUrology Case Reports, 2026
- 2609P Clinical performance of a tumor-informed whole genome-based (WGS) ctDNA assay for recurrence detection and treatment response monitoring in localized and advanced/metastatic renal cell carcinoma (RCC)Annals of Oncology, 2025
- Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trialAnnals of Oncology, 2025
- Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA MethylationJAMA Oncology, 2023
- Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell CarcinomaJAMA Oncology, 2022
- Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trialCancer, 2020
- Efficacy of Savolitinib vs Sunitinib in Patients WithMET-Driven Papillary Renal Cell CarcinomaJAMA Oncology, 2020
- Integrated Molecular Analysis of Papillary Renal Cell Carcinoma and Precursor Lesions Unfolds Evolutionary Process from Kidney Progenitor-Like CellsThe American Journal of Pathology, 2019
- Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx RenalCell, 2018
- Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx RenalCell, 2018